Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

2.

The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt.

Suizu F, Hiramuki Y, Okumura F, Matsuda M, Okumura AJ, Hirata N, Narita M, Kohno T, Yokota J, Bohgaki M, Obuse C, Hatakeyama S, Obata T, Noguchi M.

Dev Cell. 2009 Dec;17(6):800-10. doi: 10.1016/j.devcel.2009.09.007.

3.

The Akt isoforms are present at distinct subcellular locations.

Santi SA, Lee H.

Am J Physiol Cell Physiol. 2010 Mar;298(3):C580-91. doi: 10.1152/ajpcell.00375.2009.

4.

Akt1 intramitochondrial cycling is a crucial step in the redox modulation of cell cycle progression.

Antico Arciuch VG, Galli S, Franco MC, Lam PY, Cadenas E, Carreras MC, Poderoso JJ.

PLoS One. 2009 Oct 21;4(10):e7523. doi: 10.1371/journal.pone.0007523.

5.

The E3 ligase TRAF6 regulates Akt ubiquitination and activation.

Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK.

Science. 2009 Aug 28;325(5944):1134-8. doi: 10.1126/science.1175065.

6.

Insulin stimulates Akt translocation to mitochondria: implications on dysregulation of mitochondrial oxidative phosphorylation in diabetic myocardium.

Yang JY, Yeh HY, Lin K, Wang PH.

J Mol Cell Cardiol. 2009 Jun;46(6):919-26. doi: 10.1016/j.yjmcc.2009.02.015.

7.

Negative Regulation of AKT Activation by BRCA1.

Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, Yang Q.

Cancer Res. 2008 Dec 15;68(24):10040-4. doi: 10.1158/0008-5472.CAN-08-3009.

8.

PI3K/Akt: getting it right matters.

Franke TF.

Oncogene. 2008 Oct 27;27(50):6473-88. doi: 10.1038/onc.2008.313. Review.

PMID:
18955974
9.

GIDE is a mitochondrial E3 ubiquitin ligase that induces apoptosis and slows growth.

Zhang B, Huang J, Li HL, Liu T, Wang YY, Waterman P, Mao AP, Xu LG, Zhai Z, Liu D, Marrack P, Shu HB.

Cell Res. 2008 Sep;18(9):900-10. doi: 10.1038/cr.2008.75.

10.

Akt and CHIP coregulate tau degradation through coordinated interactions.

Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L.

Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3622-7. doi: 10.1073/pnas.0709180105.

11.

Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling.

Li W, Bengtson MH, Ulbrich A, Matsuda A, Reddy VA, Orth A, Chanda SK, Batalov S, Joazeiro CA.

PLoS One. 2008 Jan 23;3(1):e1487. doi: 10.1371/journal.pone.0001487.

12.

Defining the role of mTOR in cancer.

Guertin DA, Sabatini DM.

Cancer Cell. 2007 Jul;12(1):9-22. Review.

13.

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Jope RS, Yuskaitis CJ, Beurel E.

Neurochem Res. 2007 Apr-May;32(4-5):577-95. Review.

14.
15.
16.

The ubiquitin-proteasome pathway and its role in cancer.

Mani A, Gelmann EP.

J Clin Oncol. 2005 Jul 20;23(21):4776-89. Review.

PMID:
16034054
18.

Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.

Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M.

Oncogene. 2004 Jun 3;23(26):4624-35.

PMID:
15064712
19.

Structure, regulation and function of PKB/AKT--a major therapeutic target.

Hanada M, Feng J, Hemmings BA.

Biochim Biophys Acta. 2004 Mar 11;1697(1-2):3-16. Review.

PMID:
15023346
20.

Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Luo J, Manning BD, Cantley LC.

Cancer Cell. 2003 Oct;4(4):257-62. Review. No abstract available.

Items per page

Supplemental Content

Support Center